We are live on ! Find out more
IGMS

IGM Biosciences
IGMS

Delisted

IGMS was delisted on the 13th of August, 2025.

Back to rankings

1 hedge funds and large institutions have $508 invested in IGM Biosciences in 2025 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 65 closing their positions.

New
Increased
Maintained
Reduced
Closed

45.9% less ownership

Funds ownership: 45.9% → 0% (-46%)

98% less funds holding

Funds holding: 66 → 1 (-65)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

100% less capital invested

Capital invested by funds: $17.9M → $508 (-$17.9M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 65

Holders
1
Holders Change
-65
Holders Change %
-98.48%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
65
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$4.59M
2
SL
Siren LLC
Connecticut
-$3.65M
3
RG
Redmile Group
California
-$3.31M
4
S
Sanofi
France
-$1.61M
5
Goldman Sachs
Goldman Sachs
New York
-$958K
Name Holding Trade Value Shares
Change 		Change in
Stake
Osaic Holdings
1
Osaic Holdings
Arizona
$508 – – –
BBA
2
Baker Bros. Advisors
New York
– -$4.59M -4,096,210 Closed
SL
3
Siren LLC
Connecticut
– -$3.65M -3,255,826 Closed
RG
4
Redmile Group
California
– -$3.31M -2,952,131 Closed
S
5
Sanofi
France
– -$1.61M -1,438,975 Closed
Goldman Sachs
6
Goldman Sachs
New York
– -$958K -855,286 Closed
Vanguard Group
7
Vanguard Group
Pennsylvania
– -$859K -767,154 Closed
BlackRock
8
BlackRock
New York
– -$432K -385,474 Closed
Millennium Management
9
Millennium Management
New York
– -$308K -275,112 Closed
Geode Capital Management
10
Geode Capital Management
Massachusetts
– -$239K -213,273 Closed
Jane Street
11
Jane Street
New York
– -$203K -180,985 Closed
AQR Capital Management
12
AQR Capital Management
Connecticut
– -$184K -164,209 Closed
Renaissance Technologies
13
Renaissance Technologies
New York
– -$132K -117,734 Closed
Northern Trust
14
Northern Trust
Illinois
– -$120K -107,568 Closed
Two Sigma Investments
15
Two Sigma Investments
New York
– -$117K -104,290 Closed
EBA
16
Eagle Bay Advisors
New York
– -$112K -99,635 Closed
Charles Schwab
17
Charles Schwab
California
– -$100K -89,705 Closed
Two Sigma Advisers
18
Two Sigma Advisers
New York
– -$92.6K -82,700 Closed
Susquehanna International Group
19
Susquehanna International Group
Pennsylvania
– -$89.9K -80,311 Closed
State Street
20
State Street
Massachusetts
– -$85K -75,913 Closed
WP
21
Woodline Partners
California
– -$77.9K -69,576 Closed
Verition Fund Management
22
Verition Fund Management
Connecticut
– -$54.8K -48,962 Closed
Acadian Asset Management
23
Acadian Asset Management
Massachusetts
– -$50K -45,253 Closed
Marshall Wace
24
Marshall Wace
United Kingdom
– -$49.6K -44,287 Closed
Royal Bank of Canada
25
Royal Bank of Canada
Ontario, Canada
– -$45K -40,728 Closed
1
2 3

IGMS Hedge Fund Activity: Q3 2025 in Review

1 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in IGM Biosciences (IGMS) for Q3 2025, worth a combined $508 — down 100% from $17.9M a quarter earlier.

Sellers outnumbered buyers: 65 funds closed out of IGMS and 0 opened new positions — a net loss of 65 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $4.59M sold.

  • 1 institutional investor held IGM Biosciences (IGMS) as of Q3 2025, down from 66 in Q2 2025.
  • Funds reported $508 of IGM Biosciences stock for Q3 2025, down 100% quarter-over-quarter.
  • 0 funds opened new IGM Biosciences positions in Q3 2025 and 65 closed out, a net change of -65 holders.
  • The largest IGM Biosciences seller in Q3 2025 was Baker Bros. Advisors, an estimated $4.59M sold.

Based on aggregated 13F filings for Q3 2025.